AR097543A1 - COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO - Google Patents

COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO

Info

Publication number
AR097543A1
AR097543A1 ARP140103295A ARP140103295A AR097543A1 AR 097543 A1 AR097543 A1 AR 097543A1 AR P140103295 A ARP140103295 A AR P140103295A AR P140103295 A ARP140103295 A AR P140103295A AR 097543 A1 AR097543 A1 AR 097543A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
halo
cyano
or1c
hydrocarbyl
Prior art date
Application number
ARP140103295A
Other languages
English (en)
Spanish (es)
Inventor
Bi Yingzhi
Walter Gardyan Michael
Alan Green Michael
Kumi Godwin
Zhang Yulian
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of AR097543A1 publication Critical patent/AR097543A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP140103295A 2013-09-06 2014-09-03 COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO AR097543A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361874398P 2013-09-06 2013-09-06

Publications (1)

Publication Number Publication Date
AR097543A1 true AR097543A1 (es) 2016-03-23

Family

ID=52628957

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140103295A AR097543A1 (es) 2013-09-06 2014-09-03 COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO

Country Status (10)

Country Link
US (1) US20150183791A1 (cg-RX-API-DMAC7.html)
EP (1) EP3041473A1 (cg-RX-API-DMAC7.html)
JP (1) JP2016529319A (cg-RX-API-DMAC7.html)
CN (1) CN105517552A (cg-RX-API-DMAC7.html)
AR (1) AR097543A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014315075A1 (cg-RX-API-DMAC7.html)
CA (1) CA2923420A1 (cg-RX-API-DMAC7.html)
HK (1) HK1217659A1 (cg-RX-API-DMAC7.html)
TW (1) TW201542552A (cg-RX-API-DMAC7.html)
WO (1) WO2015035167A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737542B2 (en) 2013-10-11 2017-08-22 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
DK3215511T3 (da) 2014-11-06 2024-05-13 Bial R&D Invest S A Substituerede pyrazolo(1,5-a)pyrimidiner og deres anvendelse i behandlingen af medicinske lidelser
US20170333435A1 (en) 2014-11-06 2017-11-23 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
WO2016073891A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
JP7038063B2 (ja) 2016-04-06 2022-03-17 リソソーマル・セラピューティクス・インコーポレイテッド ピラゾロ[1,5-a]ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用
EP3440081A4 (en) 2016-04-06 2019-09-18 Lysosomal Therapeutics Inc. PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
EP3440083A4 (en) 2016-04-06 2019-09-18 Lysosomal Therapeutics Inc. IMIDAZO [1,5-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
US11345698B2 (en) 2016-05-05 2022-05-31 Bial—R&D Investments, S.A. Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders
AU2017261291C1 (en) 2016-05-05 2022-05-26 Bial - R&D Investments, S.A. Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
PE20200724A1 (es) * 2017-08-15 2020-07-21 Agios Pharmaceuticals Inc Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
CA3118093A1 (en) * 2018-09-28 2020-04-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of dyrk1/clk and uses thereof
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100973609B1 (ko) * 2005-03-23 2010-08-03 에프. 호프만-라 로슈 아게 mGluR2 길항제로서 아세틸렌일-피라졸로-피리미딘유도체
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
AU2007292924A1 (en) * 2006-09-07 2008-03-13 Biogen Idec Ma Inc. IRAK modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
MX2009004700A (es) * 2006-11-06 2009-05-15 Supergen Inc Derivados de imidazo[1,2-b]piridazin y pirazolo[1,5-a] pirimidina y su uso como inhibidores de proteina cinasa.
US20120058997A1 (en) * 2006-11-06 2012-03-08 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
AR067326A1 (es) * 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
CA2717034A1 (en) * 2008-02-28 2009-09-03 Pascal Furet Imidazo[1,2-b]pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease
ES2548135T3 (es) * 2008-05-13 2015-10-14 Novartis Ag Heterociclos condensados que contienen nitrógeno y composiciones de los mismos como inhibidores de quinasa
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
KR101774035B1 (ko) * 2009-10-30 2017-09-01 얀센 파마슈티카 엔.브이. 이미다조[1,2―b]피리다진 유도체 및 PDE10 저해제로서의 그의 용도
PL2710018T3 (pl) * 2011-05-19 2022-04-04 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Związki makrocykliczne jako inhibitory kinaz białkowych
CN104066730B (zh) * 2011-10-14 2017-03-08 埃姆比特生物科学公司 杂环化合物及其作为iii型受体酪氨酸激酶调节剂的用途
EP2768834B1 (en) * 2011-10-20 2016-04-27 Glaxosmithkline LLC Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
EP3235499A3 (en) * 2012-03-09 2018-01-17 Lexicon Pharmaceuticals, Inc. Inhibition of adaptor associated kinase 1 for the treatment of pain
MX347917B (es) * 2012-03-09 2017-05-17 Lexicon Pharmaceuticals Inc Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
CN105431148A (zh) * 2013-03-07 2016-03-23 加利菲亚生物公司 混合谱系激酶抑制剂及治疗方法
AU2014244083B2 (en) * 2013-03-13 2018-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity

Also Published As

Publication number Publication date
AU2014315075A1 (en) 2016-03-10
EP3041473A1 (en) 2016-07-13
US20150183791A1 (en) 2015-07-02
TW201542552A (zh) 2015-11-16
JP2016529319A (ja) 2016-09-23
CN105517552A (zh) 2016-04-20
HK1217659A1 (zh) 2017-01-20
CA2923420A1 (en) 2015-03-12
WO2015035167A1 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
AR097543A1 (es) COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
AR090292A1 (es) Compuestos basados en pirazolo[1,5-a]pirimidina, composiciones que los comprenden y metodos que los utilizan
AR097545A1 (es) COMPUESTOS A BASE DE PIRAZOLO[1,5-a]PIRIMIDINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
AR090291A1 (es) Compuestos basados en la imidazo[1,2-b]piridazina, composiciones que la comprenden y metodos que los utilizan
AR098048A1 (es) Inhibidores de fgfr4
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
NZ629025A (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
GT201400196A (es) Compuestos de heterociclilo
BR112014013974A8 (pt) derivados de sulfonamida benzílicos como moduladores de rorc
CL2016001287A1 (es) Benzamidas sustituidas y procedimiento para su uso
CU20130129A7 (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA
MX377635B (es) Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos
MX392230B (es) Pirimidina-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurogenerativos.
NI201200191A (es) Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
CR20120591A (es) Derivados de aminopirimidina como moduladores de la lrrk2
EA201390766A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ
MX394360B (es) Inhibidores de jak2 y alk2 y metodos para su uso.
AR088226A1 (es) Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas
CO6741203A2 (es) Derivados de biciclo[3,2,1]octilamida y sus usos
AR093705A1 (es) Depsipeptido y sus usos
CR20170077A (es) Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
PE20170703A1 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y metodos de uso de los mismos
EA201301334A1 (ru) Меченные радиоактивными изотопами ингибиторы глутаминилциклазы
AR097894A1 (es) Inhibidores terapéuticos de cdk8 o uso de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure